GlassScriptPhysician profile
Shereece N Wallace
NPI 1104338318
$3,241.04
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,767 · 2022: $1,303 · 2023: $137 · 2024: $34.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $714.04 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.82 | 2021-2022 | |
| Gilead Sciences, INC. | $137.81 | 2021-2022 | |
| Biogen, INC. | $132.46 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $126.44 | 2021 | |
| Glaxosmithkline, LLC. | $121.81 | 2023 | Bexsero |
| Dexcom, INC. | $120.61 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.02 | 2021-2022 | |
| Ucb, INC. | $92.72 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $87.08 | 2021 | |
| Novo Nordisk INC | $81.78 | 2022 | |
| Merck Sharp & Dohme LLC | $73.71 | 2021 | |
| Amarin Pharma, INC. | $73.18 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $58.26 | 2021-2022 | |
| Sk Life Science, INC. | $57.67 | 2021-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shereece Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.